top of page
Search

CTX310: A New Therapeutic Application of CRISPR

4 days ago
4 min read

Written By : Mansour A. Chedid, M.Eng.


The CRISPR/Cas9 system has existed in nature as a bacterial adaptive immune system for billions of years. Its potential went largely unrecognized until 2012, when Doudna and Charpentier proposed it as a programmable genome editing tool. It has since revolutionized the field of gene editing. Its rapid adoption by research laboratories across the world was fueled by its simplicity, efficiency, and affordability.


In its simplest form, the CRISPR system is used to disrupt a gene's function. A "gene knockout" is achieved by providing two components to a cell: a guide RNA (gRNA) and an endonuclease (Cas9). The gRNA escorts the endonuclease to a specific gene. Given that the gRNA's sequence determines the target on the genome, its careful design is crucial. The endonuclease then introduces a double-stranded break in the target DNA. Due to the cell's error-prone repair machinery, the target gene is rendered dysfunctional.


The scale of CRISPR/Cas9's impact was so significant that in 2023, only 11 years after it was first introduced, the FDA approved a CRISPR/Cas9-based therapy, Casgevy, for sickle cell disease, later extending its approval to beta-thalassemia (U.S. Food and Drug Administration, 2023). This was the first CRISPR-based therapy to be approved. Casgevy was the product of a collaboration between CRISPR Therapeutics, co-founded by Charpentier in 2013, and Vertex Pharmaceuticals. CRISPR Therapeutics currently has multiple drug candidates in its pipeline, targeting various diseases (CRISPR Therapeutics, n.d.). One of these, named CTX310, is in its Phase 1 clinical trial. CTX310 is being developed as an in vivo CRISPR-based therapy, aiming to address major risk factors for atherosclerotic cardiovascular disease (ASCVD) (Laffin et al., 2025).


The identification of a gene target for this treatment came from an early observation of a group of people with a naturally lower risk of ASCVD. They all had one thing in common: a naturally occurring loss of function of a protein called angiopoietin-like protein 3 (ANGPTL3) (Lorenzatti, 2026). ANGPTL3 is a liver-specific protein that inhibits lipases. In their active state, lipases break down lipids (i.e., fats). Humans who have this ANGPTL3 variant present with decreased levels of low-density lipoproteins (LDL, also referred to as "bad" cholesterol) and triglycerides (the most common type of fat in the blood) (Lorenzatti, 2026).


This finding led to the initial development of therapies to inhibit the ANGPTL3 protein. For instance, the FDA-approved evinacumab relies on monoclonal antibodies to directly bind ANGPTL3, stopping it from inhibiting the activity of lipases (i.e., fat breakdown). Although these pharmacological treatments are effective, they require long-term administration to keep LDL and triglycerides within a healthy range (Lorenzatti, 2026).


CTX310 was thus developed as a one-time solution that targets the ANGPTL3 gene itself, rather than its protein. Delivered as a single intravenous infusion, the product contains ANGPTL3-targeting gRNAs and Cas9 endonucleases. These components are packaged into lipid nanoparticles, which deliver them specifically to liver cells. In this way, the ANGPTL3 gene of liver cells is knocked out permanently (Laffin et al., 2025).


The latest data for CTX310 is promising. Its Phase 1 clinical trial, comprising 15 participants, showed no dose-limiting toxic effects or serious adverse events related to the treatment. Although the trial primarily served to determine a safe dosage range for humans, it also provided some preliminary insights into CTX310's effectiveness. At the highest dose, four participants showed a mean reduction of 48.9% in LDL cholesterol levels 60 days after administration. Additionally, at the same time point, a separate group of four participants showed a mean reduction of 55.2% in triglyceride levels (Laffin et al., 2025). Recently published updates on CTX310 highlight a sustained decrease in ANGPTL3 levels one year after the treatment was administered (Laffin et al., 2026). This data supports the one-time administration goal of CTX310.


Although its early results are encouraging, CTX310 still has a long way to go before potentially reaching the market. New treatments can take over a decade to progress between Phase 1 and regulatory approval (Elsallab et al., 2025). On the bright side, CTX310 is just one of the many proposed therapeutic applications of CRISPR. The full scale of CRISPR's impact in medicine has yet to be realized.


References


CRISPR Therapeutics. (n.d.). Pipeline. Retrieved October 3, 2026, from https://crisprtx.com/pipeline


Elsallab, M., Ouvina, M., Arfe, A., & Bourgeois, F. T. (2025). Mapping the clinical development trajectory of cell and gene therapy products. Clinical Pharmacology & Therapeutics, 117(5), 1264–1271. https://doi.org/10.1002/cpt.3512


Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Baker, J., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2025). Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. New England Journal of Medicine, 393(21), 2119–2130. https://doi.org/10.1056/NEJMoa2511778


Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Koops, R., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2026). Durability of CRISPR-Cas9 gene editing targeting ANGPTL3 with CTX310 [Letter to the editor]. New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMc2609825


Lorenzatti, A. (2026). ANGPTL3 gene editing: Promise and prudence. European Cardiology Review, 21, Article e13. https://doi.org/10.15420/ecr.2026.02


U.S. Food and Drug Administration. (2023, December 8). FDA approves first gene therapies to treat patients with sickle cell disease [Press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease


 
 
 

Comments


bottom of page